Showing results (1081-1090 of 1,186) with videos related to

Sort By:
Pageof 119
Current Oncology (Toronto, Ont.)|October 25, 2024
Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer CareJessica L Nickerson, Chloe Cyr, Riley J Arseneau, et al.
Diabetologia|November 7, 2024
NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes: the Hong Kong Diabetes BiobankRonald C W Ma, Claudia H T Tam, Yong Hou, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2013
Targeting H3K4 trimethylation in Huntington diseaseMalini Vashishtha, Christopher W Ng, Ferah Yildirim, et al.
Nature|June 29, 2022
GREM1 is required to maintain cellular heterogeneity in pancreatic cancerLinxiang Lan, Theodore Evan, Huafu Li, et al.
Cell Death and Differentiation|December 20, 2014
A unique role for p53 in the regulation of M2 macrophage polarizationL Li, D S W Ng, W-C Mah, et al.
American Journal of Health Promotion : AJHP|June 9, 2025
Associations Between Trust in Healthcare Professionals and Perceptions of Modifiability of Dementia and Stroke Risks Through Maintaining or Changing Lifestyle HabitsSharon C W Ng, Jasper R Senff, Reinier W P Tack, et al.
Journal of Gastroenterology and Hepatology|June 15, 2012
Digestive cancer management in Asia: position statements: a report on GI Oncology Summit in 2011Joseph J Y Sung, Enders K W Ng, Jaw-Town Lin, et al.
Archives of Osteoporosis|June 29, 2019
Bone measurements at multiple skeletal sites in adolescent idiopathic scoliosis-an in vivo correlation study using DXA, HR-pQCT and QCTKa Yee Cheuk, Yizhong Hu, Elisa M S Tam, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)W Yeo, M Boyer, H C Chung, et al.
Breast Cancer Research and Treatment|March 23, 2001
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluationJ A Cauley, L Norton, M E Lippman, et al.
Pageof 119